Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 m...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2016-11, Vol.175 (3), p.462-466 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 466 |
|---|---|
| container_issue | 3 |
| container_start_page | 462 |
| container_title | British journal of haematology |
| container_volume | 175 |
| creator | Thompson, Philip A. Lévy, Vincent Tam, Constantine S. Al Nawakil, Chadi Goudot, François‐Xavier Quinquenel, Anne Ysebaert, Loic Michallet, Anne‐Sophie Dilhuydy, Marie‐Sarah Van Den Neste, Eric Dupuis, Jehan Keating, Michael J. Meune, Christophe Cymbalista, Florence |
| description | Summary
Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed. |
| doi_str_mv | 10.1111/bjh.14324 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1837313943</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1837313943</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3934-f7757c7be518d04332409996394ab462c5da609c6bbf1eb3959ceec1ca2625fb3</originalsourceid><addsrcrecordid>eNp1kE1PwzAMhiMEYmNw4A-gHOHQLW76sRzHxKcqcYFzaVJXy9S1JUmZ9u_J1sENXyxLjx_ZLyHXwKbgaybXqylEPIxOyBh4EgchRHBKxoyxNAAWzUfkwto1Y8BZDOdkFKYJQMj5mHwunNFFTSstja7rwum2obqhyyyjnZ-wcZY6g4XDkm61W1EP9k43Wk7pYo86NM1hzVsMOtPaDpXT30it68vdJTmritri1bFPyMfjw_vyOcjenl6WiyxQXPAoqNI0TlUqMYZ5ySLun2FCiISLqJBREqq4LBImVCJlBSi5iIVCVKCKMAnjSvIJuR28nWm_erQu32ir0L_UYNvbHOY85eB13KN3A6r8sdZglXdGbwqzy4Hl-0BzH2h-CNSzN0dtLzdY_pG_CXpgNgBbXePuf1N-__o8KH8Asid_8w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1837313943</pqid></control><display><type>article</type><title>Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Thompson, Philip A. ; Lévy, Vincent ; Tam, Constantine S. ; Al Nawakil, Chadi ; Goudot, François‐Xavier ; Quinquenel, Anne ; Ysebaert, Loic ; Michallet, Anne‐Sophie ; Dilhuydy, Marie‐Sarah ; Van Den Neste, Eric ; Dupuis, Jehan ; Keating, Michael J. ; Meune, Christophe ; Cymbalista, Florence</creator><creatorcontrib>Thompson, Philip A. ; Lévy, Vincent ; Tam, Constantine S. ; Al Nawakil, Chadi ; Goudot, François‐Xavier ; Quinquenel, Anne ; Ysebaert, Loic ; Michallet, Anne‐Sophie ; Dilhuydy, Marie‐Sarah ; Van Den Neste, Eric ; Dupuis, Jehan ; Keating, Michael J. ; Meune, Christophe ; Cymbalista, Florence</creatorcontrib><description>Summary
Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.14324</identifier><identifier>PMID: 27611233</identifier><language>eng</language><publisher>England</publisher><subject>Aged ; Aged, 80 and over ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; atrial fibrillation ; Atrial Fibrillation - diagnosis ; Atrial Fibrillation - etiology ; Atrial Fibrillation - therapy ; chronic lymphocytic leukaemia ; Disease Management ; Female ; Hemorrhage - diagnosis ; Hemorrhage - etiology ; Hemorrhage - therapy ; Humans ; ibrutinib ; Leukemia, Lymphocytic, Chronic, B-Cell - complications ; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy ; Male ; Middle Aged ; Protein Kinase Inhibitors - adverse effects ; Protein Kinase Inhibitors - therapeutic use ; Pyrazoles - adverse effects ; Pyrazoles - therapeutic use ; Pyrimidines - adverse effects ; Pyrimidines - therapeutic use ; Retrospective Studies</subject><ispartof>British journal of haematology, 2016-11, Vol.175 (3), p.462-466</ispartof><rights>2016 John Wiley & Sons Ltd</rights><rights>2016 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3934-f7757c7be518d04332409996394ab462c5da609c6bbf1eb3959ceec1ca2625fb3</citedby><cites>FETCH-LOGICAL-c3934-f7757c7be518d04332409996394ab462c5da609c6bbf1eb3959ceec1ca2625fb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.14324$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.14324$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27611233$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Thompson, Philip A.</creatorcontrib><creatorcontrib>Lévy, Vincent</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Al Nawakil, Chadi</creatorcontrib><creatorcontrib>Goudot, François‐Xavier</creatorcontrib><creatorcontrib>Quinquenel, Anne</creatorcontrib><creatorcontrib>Ysebaert, Loic</creatorcontrib><creatorcontrib>Michallet, Anne‐Sophie</creatorcontrib><creatorcontrib>Dilhuydy, Marie‐Sarah</creatorcontrib><creatorcontrib>Van Den Neste, Eric</creatorcontrib><creatorcontrib>Dupuis, Jehan</creatorcontrib><creatorcontrib>Keating, Michael J.</creatorcontrib><creatorcontrib>Meune, Christophe</creatorcontrib><creatorcontrib>Cymbalista, Florence</creatorcontrib><title>Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>atrial fibrillation</subject><subject>Atrial Fibrillation - diagnosis</subject><subject>Atrial Fibrillation - etiology</subject><subject>Atrial Fibrillation - therapy</subject><subject>chronic lymphocytic leukaemia</subject><subject>Disease Management</subject><subject>Female</subject><subject>Hemorrhage - diagnosis</subject><subject>Hemorrhage - etiology</subject><subject>Hemorrhage - therapy</subject><subject>Humans</subject><subject>ibrutinib</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - complications</subject><subject>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Protein Kinase Inhibitors - therapeutic use</subject><subject>Pyrazoles - adverse effects</subject><subject>Pyrazoles - therapeutic use</subject><subject>Pyrimidines - adverse effects</subject><subject>Pyrimidines - therapeutic use</subject><subject>Retrospective Studies</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kE1PwzAMhiMEYmNw4A-gHOHQLW76sRzHxKcqcYFzaVJXy9S1JUmZ9u_J1sENXyxLjx_ZLyHXwKbgaybXqylEPIxOyBh4EgchRHBKxoyxNAAWzUfkwto1Y8BZDOdkFKYJQMj5mHwunNFFTSstja7rwum2obqhyyyjnZ-wcZY6g4XDkm61W1EP9k43Wk7pYo86NM1hzVsMOtPaDpXT30it68vdJTmritri1bFPyMfjw_vyOcjenl6WiyxQXPAoqNI0TlUqMYZ5ySLun2FCiISLqJBREqq4LBImVCJlBSi5iIVCVKCKMAnjSvIJuR28nWm_erQu32ir0L_UYNvbHOY85eB13KN3A6r8sdZglXdGbwqzy4Hl-0BzH2h-CNSzN0dtLzdY_pG_CXpgNgBbXePuf1N-__o8KH8Asid_8w</recordid><startdate>201611</startdate><enddate>201611</enddate><creator>Thompson, Philip A.</creator><creator>Lévy, Vincent</creator><creator>Tam, Constantine S.</creator><creator>Al Nawakil, Chadi</creator><creator>Goudot, François‐Xavier</creator><creator>Quinquenel, Anne</creator><creator>Ysebaert, Loic</creator><creator>Michallet, Anne‐Sophie</creator><creator>Dilhuydy, Marie‐Sarah</creator><creator>Van Den Neste, Eric</creator><creator>Dupuis, Jehan</creator><creator>Keating, Michael J.</creator><creator>Meune, Christophe</creator><creator>Cymbalista, Florence</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201611</creationdate><title>Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study</title><author>Thompson, Philip A. ; Lévy, Vincent ; Tam, Constantine S. ; Al Nawakil, Chadi ; Goudot, François‐Xavier ; Quinquenel, Anne ; Ysebaert, Loic ; Michallet, Anne‐Sophie ; Dilhuydy, Marie‐Sarah ; Van Den Neste, Eric ; Dupuis, Jehan ; Keating, Michael J. ; Meune, Christophe ; Cymbalista, Florence</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3934-f7757c7be518d04332409996394ab462c5da609c6bbf1eb3959ceec1ca2625fb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>atrial fibrillation</topic><topic>Atrial Fibrillation - diagnosis</topic><topic>Atrial Fibrillation - etiology</topic><topic>Atrial Fibrillation - therapy</topic><topic>chronic lymphocytic leukaemia</topic><topic>Disease Management</topic><topic>Female</topic><topic>Hemorrhage - diagnosis</topic><topic>Hemorrhage - etiology</topic><topic>Hemorrhage - therapy</topic><topic>Humans</topic><topic>ibrutinib</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - complications</topic><topic>Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Protein Kinase Inhibitors - therapeutic use</topic><topic>Pyrazoles - adverse effects</topic><topic>Pyrazoles - therapeutic use</topic><topic>Pyrimidines - adverse effects</topic><topic>Pyrimidines - therapeutic use</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Thompson, Philip A.</creatorcontrib><creatorcontrib>Lévy, Vincent</creatorcontrib><creatorcontrib>Tam, Constantine S.</creatorcontrib><creatorcontrib>Al Nawakil, Chadi</creatorcontrib><creatorcontrib>Goudot, François‐Xavier</creatorcontrib><creatorcontrib>Quinquenel, Anne</creatorcontrib><creatorcontrib>Ysebaert, Loic</creatorcontrib><creatorcontrib>Michallet, Anne‐Sophie</creatorcontrib><creatorcontrib>Dilhuydy, Marie‐Sarah</creatorcontrib><creatorcontrib>Van Den Neste, Eric</creatorcontrib><creatorcontrib>Dupuis, Jehan</creatorcontrib><creatorcontrib>Keating, Michael J.</creatorcontrib><creatorcontrib>Meune, Christophe</creatorcontrib><creatorcontrib>Cymbalista, Florence</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Thompson, Philip A.</au><au>Lévy, Vincent</au><au>Tam, Constantine S.</au><au>Al Nawakil, Chadi</au><au>Goudot, François‐Xavier</au><au>Quinquenel, Anne</au><au>Ysebaert, Loic</au><au>Michallet, Anne‐Sophie</au><au>Dilhuydy, Marie‐Sarah</au><au>Van Den Neste, Eric</au><au>Dupuis, Jehan</au><au>Keating, Michael J.</au><au>Meune, Christophe</au><au>Cymbalista, Florence</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2016-11</date><risdate>2016</risdate><volume>175</volume><issue>3</issue><spage>462</spage><epage>466</epage><pages>462-466</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%). Data to guide optimal management are lacking and clinical practice guidelines are urgently needed.</abstract><cop>England</cop><pmid>27611233</pmid><doi>10.1111/bjh.14324</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2016-11, Vol.175 (3), p.462-466 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1837313943 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Aged, 80 and over Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use atrial fibrillation Atrial Fibrillation - diagnosis Atrial Fibrillation - etiology Atrial Fibrillation - therapy chronic lymphocytic leukaemia Disease Management Female Hemorrhage - diagnosis Hemorrhage - etiology Hemorrhage - therapy Humans ibrutinib Leukemia, Lymphocytic, Chronic, B-Cell - complications Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Male Middle Aged Protein Kinase Inhibitors - adverse effects Protein Kinase Inhibitors - therapeutic use Pyrazoles - adverse effects Pyrazoles - therapeutic use Pyrimidines - adverse effects Pyrimidines - therapeutic use Retrospective Studies |
| title | Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T17%3A55%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Atrial%20fibrillation%20in%20CLL%20patients%20treated%20with%20ibrutinib.%20An%20international%20retrospective%20study&rft.jtitle=British%20journal%20of%20haematology&rft.au=Thompson,%20Philip%20A.&rft.date=2016-11&rft.volume=175&rft.issue=3&rft.spage=462&rft.epage=466&rft.pages=462-466&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.14324&rft_dat=%3Cproquest_cross%3E1837313943%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1837313943&rft_id=info:pmid/27611233&rfr_iscdi=true |